Southern Shuanglin insiders buy $3.9m in shares
Southern Shuanglin Bio-Pharmacy (SZSE:000403) announced that key company personnel have bought 183,500 shares for approximately RMB 3,867,383 ($500,027) since December 28, 2024. The purchases, part of an insider buy program, involved members of the board, supervisors, senior management, and the general manager of subsidiary Guangdong Southern Shuanglin Bio-Pharmacy. The insiders stated the move reflects confidence in the company's prospects and commitment to shareholder value. The original buyback program, targeting at least RMB 5 million (USD $69,000) in shares, continues.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Southern Shuanglin Bio-Pharmacy publishes news
Free account required • Unsubscribe anytime